Financials in USD. Standardized financial statements.
A compact view of how Recordati Industria Chimica e Farmaceutica S.p.A. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.62B | $2.34B | $2.08B | $1.85B | $1.58B | $1.45B | $1.48B | $1.35B | $1.29B | $1.15B |
| Revenue Growth? | +11.8% | +12.4% | +12.4% | +17.3% | +9.1% | -2.2% | +9.6% | +5.0% | +11.6% | 0.0% |
| Cost of Revenue? | $830.70M | $741.29M | $600.76M | $566.74M | $427.73M | $406.83M | $436.90M | $395.57M | $382.75M | $360.96M |
| Gross Profit? | $1.79B | $1.60B | $1.48B | $1.29B | $1.15B | $1.04B | $1.04B | $956.67M | $905.37M | $792.98M |
| Gross Margin? | +68.3% | +68.3% | +71.1% | +69.4% | +72.9% | +71.9% | +70.5% | +70.7% | +70.3% | +68.7% |
| Operating Expenses? | $1.07B | $961.41M | $923.56M | $792.26M | $647.03M | $568.09M | $575.27M | $510.91M | $496.63M | $452.93M |
| Operating Income? | $719.74M | $638.86M | $558.01M | $437.33M | $490.19M | $469.02M | $465.27M | $442.22M | $406.49M | $327.42M |
| EBITDA? | $887.00M | $795.75M | $708.56M | $559.35M | $578.35M | $566.83M | $537.37M | $501.50M | $456.66M | $377.71M |
| Income Before Tax | $581.27M | $547.18M | $491.04M | $401.44M | $463.35M | $455.66M | $444.14M | $417.94M | $389.12M | $317.28M |
| Income Tax Expense | $137.65M | $130.68M | $101.82M | $89.10M | $77.38M | $100.63M | $75.28M | $105.51M | $100.32M | $79.85M |
| Net Income? | $443.62M | $416.51M | $389.21M | $312.34M | $385.97M | $354.98M | $368.82M | $312.38M | $288.76M | $237.41M |
| EPS? | $2.15 | $2.02 | $1.86 | $1.52 | $1.87 | $1.73 | $1.80 | $1.53 | $1.40 | $1.15 |
| Diluted EPS? | $2.12 | $1.99 | $1.86 | $1.49 | $1.85 | $1.70 | $1.76 | $1.49 | $1.38 | $1.14 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality